

The benefits for General Practice
Veterinarians and Veterinary
Oncologists

DEVELOP & REVOLUTIONISE

**K9-LiquiDX™ revolutionises how we
detect early relapse and monitor cancer.
The only thing that you need is a routine,
minimally invasive blood draw.**

No sedation or anaesthesia is needed in
the majority of animals. Earlier relapse
detection allows for earlier treatment and
potentially better outcomes!

-  Greater quality of life for cancer patients.
-  Potential for personalisation of treatment.
-  Build trust with pet owners by offering advanced diagnostic tools like K9-LiquiDX™ which demonstrates a commitment to providing the best care possible.
-  Better allocation of resources and time for the practice.
-  Increase revenue with more treatment options via earlier relapse detection, whilst potentially giving better health outcomes.



CONTACT US...

T: 0131 563 6800

E: enquiries@cancandiagnostics.com

www.cancandiagnostics.com

CanCan Diagnostics
Roslin Innovation Centre,
Easter Bush Campus,
Edinburgh EH25 9RG



REVOLUTIONISING CANINE HEALTH

Through early relapse detection and
precision cancer monitoring.



K9-LIQUIDX

We care about your pets

EARLY DIAGNOSIS & MONITORING OF CANINE CANCER.

Cancer is one of the leading causes of death in dogs, with between *25-50% of animals developing it in their lifetime. We developed a cell-free DNA next generation sequencing-based liquid biopsy panel for aiding diagnosis and disease monitoring for canine cancer.

We have developed the worlds 1st minimal residual disease (MRD) test specifically designed for dogs marking a new era in canine cancer care, offering veterinarians and pet owners a powerful tool for early relapse detection and precision cancer monitoring.

Cell-free DNA are DNA fragments that are released to blood when cells die. The isolated DNA is then sequenced using a custom-build next-generation sequencing enrichment panel and state-of-the-art analysis pipeline.

*Relates to % of dogs above 10years of age that are predisposed breeds.

ABOUT K9-LIQUIDX™

"K9-LiquidDx™ offers minimally-invasive, quick to perform and precise canine cancer monitoring, raising the standard of care for your patients and ensuring peace of mind for pet owners."



Early Relapse Detection:

Monitors cancers which are currently difficult to monitor and detect relapse earlier than current methods.



Early Intervention:

Early intervention capabilities that enhance patient outcomes.



Quality of Life:

Increase the animal's quality of life and owners experience.



Comprehensive Profiling:

We can provide a comprehensive genetic profile of cancer, allowing for personalised treatment strategies tailored to the individual animal's needs.



Minimally-Invasive with Precision:

Liquid biopsies only require a quick blood draw, minimising stress, and discomfort for the animal.

OUR PROCESS:


01:

Dying cells release DNA into the bloodstream.




02:

Take 5-9ml of blood from your patient.



03:

Gently mix the blood by inverting it 10 times.




04:

Secure inside a CanCan box and ship to the lab.

05:

DNA isolated & undergoes genetic sequencing.



06:

Our experts issue report.